Ribbon's automated, enzyme-based InfiniSynth platform, can provide DNA molecules without size or sequence limitations, at a high level of accuracy and speed.
In early 2022 the company closed an €18 million Series A financing.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze